Artelo Biosciences (ARTL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Artelo Biosciences (ARTL) is Moderate Underperform.

The composite score behind that read is -0.42, weighing +0.00 of bullish evidence against -0.60 bearish.

Artelo Biosciences last closed at $3.26, -3.26% on the session.

Against the IVW growth benchmark the position is -4.06% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for ARTL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Artelo Biosciences in the 2nd percentile on return on equity, where 100 is best.

Artelo Biosciences is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.85M.

StockMap tracks Artelo Biosciences as the 148th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Artelo Biosciences ranks 150th of 151 in the group, against a group median of -0.08.